Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
1(16.7%)
Phase 3
1(16.7%)
6Total
Phase 2(4)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02515734Phase 2Unknown

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab

Role: lead

NCT01227239Phase 1Unknown

Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting

Role: lead

NCT00287755Phase 2Completed

Clinical Trial of Chemosensitivity Test

Role: lead

NCT00514163Phase 2Completed

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Role: lead

NCT00639327Phase 2Completed

Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

Role: lead

NCT00287768Phase 3Completed

Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

Role: lead

All 6 trials loaded